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Abstract: 
Previous studies have shown that iron deficiency (ID) increases brain manganese (Mn), but specific regional 
changes have not been addressed. Weanling rats were fed one of three semipurified diets: control (CN), iron 
deficient (ID), or iron deficient/manganese fortified (IDMn+). Seven brain regions were analyzed for Mn 
concentration and amino acid (glutamate, glutamine, taurine, γ-aminobutyric acid) concentrations. Both ID and 
IDMn+ diets caused significant (p<0.05) increases in Mn concentration across brain regions compared to CN. 
The hippocampus was the only brain region in which the IDMn+ group accumulated significantly more Mn 
than both the CN and ID groups. ID significantly decreased GABA concentration in hippocampus, caudate 
putamen, and globus pallidus compared to CN rats. Taurine was significantly increased in the substantia nigra 
of the IDMn+ group compared to both ID and CN. ID also altered glutamate and glutamine concentrations in 
cortex, caudate putamen, and thalamus compared to CN. In the substantia nigra, Mn concentration positively 
correlated with increased taurine concentration, whereas in caudate putamen, Mn concentration negatively 
correlated with decreased GABA. These data show that ID is a significant risk factor for central nervous sys-
tem Mn accumulation and that some of the neurochemical alterations associated with ID are specifically 
attributable to Mn accumulation. 
Index Entries: Rat; brain; iron deficiency; manganese; GABA; glutamate. 
 
Article: 
INTRODUCTION 
Iron deficiency (ID) is one of the most prevalent nutritional problems in the world, affecting approximately 2 
billion people (1). ID is also a known risk factor for metal toxicity (e.g., cadmium, aluminum, lead) (2–4), with 
an inverse relationship existing between dietary iron (Fe) content and the gastrointestinal absorption of a host of 
other metals. Fe also shares similar absorption mechanisms with essential divalent metals, particularly 
manganese (Mn) (5), and a deficiency of one of these minerals in the diet can lead to excess absorption of the 
other mineral. For example, high Fe intakes decrease gastrointestinal Mn absorption, whereas ID leads to 
increased Mn absorption, (6,7). In addition, rats exposed to high doses of Mn exhibit altered brain Fe 
metabolism (8). Furthermore, ID is associated with increased Mn accumulation in the brain (9,10); however, 
brain regional changes are unknown. 
 
Both Mn and Fe transport to extrahepatic tissues, including the brain, is dependent on transferrin-mediated 
endocytosis (11,12). Because ID causes increased brain regional transferrin (Tf) and transferrin receptor (TfR) 
concentrations in a heterogeneous fashion (13–15), it is likely that ID-associated brain Mn accumulation occurs 
in a heterogeneous manner. High levels of manganese in globus pallidus, caudate putamen, and sub-thalamic 
nuclei have contributed to the vulnerability of the striatum to manganese toxicity (16,17). Accordingly, a goal 
of this study was to investigate if ID is associated with increased accumulation of Mn, especially in brain 
regions that inherently contain high Mn levels (e.g., striatum). 
 
The neurobiological sequelae of ID include alterations in behavior, cognition, and neurotransmitter metabolism 
(18). Over three decades ago, ID was linked to decreased dopamine D2 receptors in striatum (19,20), and, 
presently, it is well established that ID leads to increased extracellular dopamine (21–23) and decreased 
dopamine transporter and dopamine receptor functioning (24,25). There is growing evidence that ID is 
associated with perturbation in additional neurotransmitter levels [e.g., γ-aminobutyric acid (GABA), glutamate, 
and serotonin] (26). However, a direct effect of ID on these neurotransmitters has yet to be determined. 
Accordingly, a secondary goal of this study was to examine the effect of ID and/or Mn accumulation on brain 
regional concentrations of GABA, glutamate, and aspartate. 
 
Glutamate is the most prevalent excitatory neurotransmitter in the brain (27), whereas GABA is the most 
abundant inhibitory neurotransmitter in the brain (28). Cortical glutamate afferents project into the striatum 
where, in concert with GABA and dopamine, motor behaviors are controlled (29). Glutamate is converted to 
GABA by decarboxylation via glutamate decarboxylase (GAD) and is degraded via GABA-transaminase. 
Altered GABA metabolism as a result of ID has been shown (26), but absolute changes in GABA concentration 
were not detected. Further-more, Li’s study demonstrated increased glutamate concentration as a 
result of ID, caused by decreased GAD activity. Reports of GABA concentrations in the rat brain upon 
manganese exposure are inconsistent. For example, exposure to 6 mg Mn/kg/d led to a significant increase in 
brain manganese concentrations and significant decrease in GABA concentrations (30). Another report showed 
that rats exposed to 20 mg Mn/kg/d had significantly increased brain manganese and GABA concentrations 
(31). Accordingly, it appears that a relationship exists between the severity of Mn exposure and GABA 
concentrations, with lower Mn exposure leading to decreased GABA, and high Mn exposure leading to 
increased GABA concentrations. 
 
Taurine is present in high concentrations in the mammalian central nervous system (CNS), particularly in the 
striatum. It has been implicated as a neuroprotectant (32) and a possible neurotransmitter. Past studies have 
focused on its relationship with GABA in striatum and substantia nigra (33). Briefly, taurine injected into rat 
substantia nigra induces inhibition of dopamine neurons (34) and GABA-like behaviors (35). Furthermore, 
taurine has been shown to interact with GABAA receptors (36), which are abundant in the substantia nigra. Mn 
exposure has been shown to increase taurine transporter expression in astrocytes (37) and increase taurine 
concentration in the cerebellum (31), potentially representing adaptive responses to Mn-induced oxidative 
damage (38,39). 
 
The first goal of this study was to examine the effect of ID on Mn accumulation in seven brain regions: cortex, 
cerebellum, hippocampus, caudate putamen, globus pallidus, substantia nigra, and thalamus. These brain 
regions include those known to be vulnerable to Mn toxicity (e.g., globus pallidus, caudate putamen, thalamus), 
as well as regions less sensitive to Mn (e.g., cortex). We also included an ID diet fortified with 100 mg Mn/kg 
diet (10 mg Mn/kg diet is the recommended level) to examine the interaction between dietary Mn and brain Mn 
concentration in response to ID. The working hypothesis was that ID will lead to Mn accumulation in the brain 
and that an ID diet that is fortified with Mn will not increase brain Mn accumulation beyond levels that are 
associated with ID per se. Furthermore, we hypothesized that ID will increase Mn accumulation in Mn-sensitive 
―target‖ regions (i.e., thalamus, caudate putamen, and globus pallidus) to a greater extent than Mn-insensitive 
―nontarget‖ (i.e., cortex) brain regions. The final goal of this study was to measure neurochemical changes in 
these seven brain regions as a result of ID and to determine if Mn accumulation correlates with these changes. 
 
MATERIALS AND METHODS  
Animals 
Male 21-d-old Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN) were randomly divided into 
three dietary treatment groups: control (CN; 35 mg Fe/kg, 10 mg Mn/kg diet), iron deficient (ID; 4 mg Fe/kg, 
10 mg Mn/kg diet), and iron deficient/manganese supplemented (IDMn+; 4 mg Fe/kg, 100 mg Mn/kg diet). 
Diets were obtained from Bio-Serv (Frenchtown, NJ) and certified for mineral content. Rats had free access to 
food and water 24 h/d, and the lights were turned off between 1800 and 0600 h. Room temperature was 
maintained at 25 ± 1°C. After 6 wk of dietary treatment, the rats were killed and their brains were removed for 
mineral and neurochemical analyses. The Wake Forest University School of Medicine Animal Care and Use 
Committee approved all of the animal procedures. 
 
Hematological Measurements 
Hematocrit was measured weekly via blood samples acquired by tail prick. It was determined by centrifugation 
of blood collected into heparinized microcapillary tubes. Blood samples were collected at the end of the 
experiment into heparinized tubes; aliquots were used for hematocrit and hemoglobin (procedure no. 525; 
Sigma Chemical, St. Louis, MO) measurements. The remaining blood was cooled to 4°C and centrifuged in a 
clinical centrifuge for 15 min to separate cells from plasma. Plasma was frozen at –80°C until analyzed for Fe 
and transferrin (Tf). Plasma Fe was measured with the ADVIA 1650
TM
 (Bayer Corp., Tarrytown, NY) and Tf 
by a turbidimetric immunoassay (40). 
 
Brain Mn 
Brains were dissected into seven regions: caudate putamen, globus pallidus, thalamus, hippocampus, substantia 
nigra, cerebellum, and cortex. Neutron activation analysis (NAA) was used to measure Mn and Fe in the brain 
regions. Unfortunately, NAA was not sufficiently sensitive enough to detect Fe in all brain regions. Therefore, 
only Mn concentrations are reported. Samples were irradiated for 60 s each in PULSTAR pneumatic terminus at 
900 kWth. Samples were decayed for approximately 60 min and counted for 10 min each on a gamma 
spectroscopy system analyzing for Mn. 
 
Amino Acid Analysis 
Amino acid standards were purchased from Sigma Chemicals (Sigma Aldrich, Natick, MA). Brain amino acid 
concentrations were measured according to a published method (41). Briefly, tissues were homogenized in 4°C 
absolute methanol (#A 454-4; Fisher Scientific, Fairlawn, NJ). Homoserine was added as an internal standard 
and several concentrations of the amino acids were added to brain extracts and processed in parallel for 
quantifying unknowns. Homogenates were centrifuged at 1000 g for 10 min and the supernatants were dried at 
37°C under a stream of dry nitro-gen. The dried samples were stored at –20°C until analyzed. Samples were 
reconstituted with methanol (A 454-4) and reacted with OPT reagent (100 mg O-pthaldialdehyde in 0.5 mL 
methanol, 100 µL of 2-mercaptoethanol in 1.9 mL of 0.4 M borate, pH 9.5) for 2 min and injected into a 
gradient high-performance liquid chromatography (HPLC) system (Gilson Model 201) using an autoinjector 
(Gilson 401 and 231). A C18 reversed-phase column (0.46 × 15 cm, 5 µm) was used with fluorometric detection 
(Gilson 121) (excitation 305–395 nm, 430–470 nm). The mobile phase was 0.1 M sodium acetate, pH 6.2, 
containing 0.1 µM EDTA and increasing concentrations of methanol (15–50%) with a 1.3-mL/p min flow rate. 
Retention times in minutes were as follows: aspartate (Asp), 2.35; glutamate (glu), 3.47; glutamine (gln), 7.9; 
homoserine (Hser), 9.9; glycine (Gly), 11.16; taurine (Taur), 17.0; γ-amino butyric acid (GABA), 20.2. 
 
Statistical Analysis 
The data were analyzed with the SAS system for Windows v6.12 statistical analysis package (SAS, Cary, NC). 
Data were examined for normality of distribution and presence of outliers. Data two standard deviations above 
or below the mean were considered outliers. One-way analysis of variance was used to test for the effects of 
dietary treatment on clinical parameters. Simple repeated-measures analysis of variance with repeated-measures 
factors (brain regions) and between-groups factors (dietary treatment) was used to test for interactions between 
dietary treatments and brain regions for amino acid and mineral data. Tukey’s HSD post hoc test was used to 
evaluate mean differences. The α level for the analyses was p<0.05 
 
RESULTS 
Body Weights, Tissue Weights, and Hematology 
Both ID diets (ID and IDMn+) caused significant decreases in body weight (Table 1). Hematocrit and 
hemoglobin were significantly lower in the ID and IDMn+ groups, indicating severe anemia (Table 1). Further-
more, plasma transferrin (higher than controls) and iron (lower than controls) concentrations were characteristic 
of anemia in the ID and IDMn+ groups (Table 1) and consistent with earlier reports of ID (13–15,42). 
 
 
 
Brain Regional Mn Concentrations 
Both iron-deficient diets (ID and IDMn+) caused a significant increase (p<0.05) in Mn concentration in all 
brain regions compared to controls (CN), except substantia nigra, where the trend was similar but the p-value 
was not statistically significant (p=0.091) (Table 2). The IDMn+ diet did not significantly increase Mn 
concentration in any brain region compared to the ID diet, except in the hippocampus (CN<ID<IDMn+). 
 
 
 
 
Brain Regional Amino Acid Concentrations 
Amino acid concentrations in the seven brain regions are summarized in Table 3. The cortex, glutamate, and 
glutamine were significantly decreased (p<0.05) in both ID and IDMn+ groups compared to CN. However, 
glutamate concentration was significantly higher (p<0.05) in the caudate putamen of IDMn+ rats compared to 
ID and CN. Glutamine and GABA concentrations were significantly reduced (p<0.05) in the caudate putamen 
of ID and IDMn+ rats compared to CN. GABA concentration was also decreased in the hippocampus (ID and 
IDMn+) and the globus pallidus (IDMn+) compared to CN rats (p<0.05). Taurine concentration in the 
substantia nigra of IDMn+ rats was significantly higher (p<0.05) than in CN and ID rats. 
 
Correlational Analysis 
Only two significant relationships emerged when Mn concentration was correlated with each of the amino acids 
in all of the brain regions. Mn concentration significantly correlated with increased taurine concentration in the 
substantia nigra (r = 0.65; p < 0.05) (Fig. 1), and in the caudate putamen, increased Mn negatively correlated 
with GABA concentration (r = –0.54; p < 0.05) (Fig. 2). 
 
 
 
DISCUSSION 
Several novel findings emerged from this study. First, although ID caused a significant increase in brain Mn 
concentration, increased dietary Mn (IDMn+ diet) did not increase brain Mn concentration beyond the level 
associated with ID, except in the hippocampus. Second, ID led to brain-region-specific alterations in amino acid 
concentrations (e.g., GABA concentration was significantly decreased in hippocampus, caudate putamen, and 
globus pallidus, but not other regions). Finally, increased taurine in the substantia nigra was highly correlated 
with Mn concentration. 
 
Although it was previously shown that ID increases Mn concentration in rat brain (9,10), this is the first study to 
assess ID-associated region-specific changes in brain Mn levels. ID led to a significant increase (p<0.05) in the 
Mn concentration of all brain regions, except substantia nigra (p=0.091) (Table 2). 
 
Brain regional Mn concentrations were measured with NAA, which offers highly sensitive detection for Mn. 
Unfortunately, NAA has a very low sensitivity for Fe detection. Nevertheless, Fe measurements were 
detected in cerebellum, hippocampus, cortex, and thalamus and were similar to levels reported in the literature 
(14,15,24). ID caused a 20–40% decrease in Fe concentration in these brain regions, with hippocampus showing 
the greatest reduction in iron concentration. 
 
Iron deficiency leads to a significant increase in transferrin (Tf), transferrin receptor (TfR), and a decrease in Fe 
concentrations in various rat brain regions (13–15). Therefore, because ID causes increased Tf and TfR 
heterogeneously in the brain, it was logical to expect increased Mn in the brain in a heterogeneous manner, 
given earlier findings that link Mn trans-port to TfR endocytosis (43). Although we did not measure brain Tf 
levels in these rats, it is interesting to note that ID increased hippocampal and cortical Tf more robustly than 
other regions (14) and that the IDMn+ diet caused a significant increase in Mn compared to the ID diet 
exclusively in these two regions (Table 2). Hence, ID-induced Mn accumulation occurred in a heterogeneous 
fashion in the brain, with regions that have been shown to respond profoundly to ID with increased Tf and TfR, 
accumulating more Mn. 
 
An additional novel finding of these studies suggests that even at nor-mal dietary Mn concentration, ID is 
sufficient to induce brain regional Mn accumulation (i.e., increased dietary manganese [IDMn+ diet] was not 
needed to raise regional Mn concentrations). The data also corroborate other studies that have shown that even 
under extreme conditions of Mn exposure, brain Mn concentration were not increased beyond twofold to 
threefold (44). The public health ramification of this observation is pro-found, for segments of the population in 
which ID is most prevalent (pregnant women, adolescents, toddlers) are at risk for increased brain Mn 
accumulation, even in the absence of environmental Mn exposure. 
 
Numerous reports show that ID is associated with disturbances in neurotransmitter metabolism. For example, 
ID is linked to decreased dopamine D2 and D1 receptor densities (19,20,25), increased extracellular dopamine 
(21–23), and decreased dopamine uptake and dopamine transporter density (24). Similarly, manganese 
neurotoxicity is associated with altered neurotransmitter metabolism. Manganese is linked to alterations of 
dopamine, glutamate, and GABA metabolism in rats (16,31,45,46). 
 
In addition to the known disturbances in dopamine metabolism, ID affects GABA metabolism in rat brain 
tissues (26). Whereas the absolute GABA concentration was not different from control levels, GAD activity 
was significantly lower in ID rats (26). In contrast, we found that both ID diets (ID and IDMn+) caused a 
significant decrease in GABA concentration in the hippocampus and caudate putamen, whereas only the 
IDMn+ diet decreased GABA concentration in the globus pallidus (Table 3). The level of ID was more severe 
in our rats than in Li’s (e.g., Hb 46 g/L vs 84 g/L; Hct 16% vs 31%, respectively). Therefore, because our study 
employed a more severe ID condition, we observed a significant ID-dependent decrease in GABA 
concentration and Li (26) did not, even though the overall amino acid concentrations in each brain region tested 
were similar in both studies. Consistent with the caudate putamen’s known sensitivity to Mn-induced alterations 
in neurochemistry (16,45), GABA concentration in this brain region negatively correlated with Mn 
concentration (Fig. 2). This finding is in accordance with a previous study in which Mn accumulation in rat 
brains led to decreased GABA concentrations (30). It is also important to note that the increased dopamine 
levels in caudate putamen observed in ID rats (21–23) may be associated with decreased GABA concentration. 
It is well established that striatonigral GABAergic neurons are inhibitory neurons, which project onto the 
substantia nigra. Thus, it is probable that decreased striatal GABA concentration is indicative of attenuated 
inhibitory signals to the nigrostriatal dopaminergic pathway (i.e., substantia nigra), thereby contributing to the 
observed elevation of dopamine levels in caudate putamen. 
 
Glutamate (Glu) is increased in striatum of ID rats (26). This ID-associated increase in striatal Glu was the 
result of decreased GAD (rate-limiting enzyme in GABA formation) activity, according to Li (26). Our study 
showed that in caudate putamen, the IDMn+ diet caused a significant increase in Glu, but both ID diets caused a 
decrease in cortical Glu levels. Because glutamatergic afferents projecting into striatum control motor behavior, 
decreased cortical Glu could exacerbate and/or precipitate motor behavioral changes associated with ID 
(20,25,47,48). A plausible explanation for this significant decrease in cortical Glu concentration is that ID-
induced Mn accumulation caused attenuation of Glu recycling. It has been suggested that Glu uptake by 
astrocytes, its conversion to glutamine (Gln) via glutamine synthetase, and deamination to Glu is the primary 
Glu recycling pathway (49–51). Indeed, Mn exposure is associated with decreased Glu uptake in astrocytes 
(37,52). Furthermore, the decreased Gln observed in caudate putamen, cortex, and thalamus associated with ID 
might be caused by Mn-induced attenuation of astrocytic Glu uptake. The implications of the potential 
neurotoxic effects of this increased Glu (53) secondary to ID are profound and extend our knowledge of 
neurobiological sequelae of ID from primarily neurochemical to neurotoxic. 
 
Taurine concentration was significantly increased in substantia nigra resulting from the IDMn+ diet compared 
with CN or ID diets. There is no known link between ID and taurine levels in the brain. However, Mn is linked 
with increased taurine transporter gene expression in astrocytes (37). Taurine is one of the most abundant amino 
acids in the brain, particularly in the striatum. It is thought to be a neuroprotectant, as well as a putative 
neurotransmitter (33). Its role as a neurotransmitter is putatively mediated via interactions with GABAA 
receptors (36). A potential explanation for the significant correlation between Mn and taurine concentration in 
substantia nigra is that Mn accumulation leads to an adaptive response (i.e., increased taurine) (39), especially 
in the substantia nigra, an area that is vulnerable to oxidative processes (e.g., Parkinson’s disease). 
 
In conclusion, the present study establishes that ID leads to brain Mn accumulation in a heterogeneous fashion. 
Further, the IDMn+ diet does not enhance brain Mn accumulation beyond the ID diet per se, except in the 
hippocampus, a region shown to respond vigorously to ID with an increase in Tf and TfR (14,15). Our data 
unequivocally support a role for Fe in the metabolism of certain amino acid neurotransmitters, namely 
glutamate and GABA. Both amino acids are critical for proper functioning of the striatum, which is known to be 
perturbed in ID. Thus, this study broadens the understanding of neurochemical alterations in ID from being 
solely associated with dopamine to identifying changes in glutamate and GABA metabolism as a consequence 
of ID. Additionally, the significant correlation between caudate putamen concentration of GABA and Mn 
warrant further investigation, particularly because this relationship is brain region-specific (i.e., ID-associated 
Mn accumulation may account for some of the neurochemical alterations formerly attributed to brain Fe loss). 
Finally, taurine concentration was significantly correlated with Mn concentration in the substantia nigra, 
potentially representing a neurochemical change that is specific to combined ID and Mn fortification (i.e., not 
observed with ID alone). The ID diets utilized in this study were sufficient to ascertain changes in brain Mn and 
amino acid transmitters associated with the lack of Fe. A less severe ID diet (10–15 mg Fe/kg diet) will be 
tested in future studies to examine these issues under less physiologically extreme conditions. 
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